The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Mol Cancer. 2023 May 6;22(1):80. doi: 10.1186/s12943-023-01783-1.
Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing technologies, with the powerful unbiased analysis of cellular heterogeneity and molecular patterns at unprecedented resolution, have greatly advanced our understanding of immunology and oncology. In this review, we summarize the recent applications of single-cell sequencing technologies in CAR T-cell therapy, including the biological characteristics, the latest mechanisms of clinical response and adverse events, promising strategies that contribute to the development of CAR T-cell therapy and CAR target selection. Generally, we propose a multi-omics research mode to guide potential future research on CAR T-cell therapy.
嵌合抗原受体 (CAR) T 细胞疗法在癌症免疫疗法方面取得了显著进展，但由于一些机制尚不清楚的挑战，限制了其广泛的临床应用。单细胞测序技术以空前的分辨率对细胞异质性和分子模式进行强大的无偏分析，极大地促进了我们对免疫学和肿瘤学的理解。在这篇综述中，我们总结了单细胞测序技术在 CAR T 细胞疗法中的最新应用，包括 CAR T 细胞的生物学特性、临床反应和不良事件的最新机制、有助于 CAR T 细胞疗法发展和 CAR 靶点选择的有前景的策略。总的来说，我们提出了一种多组学研究模式，以指导未来对 CAR T 细胞疗法的潜在研究。
